Hydroxychloroquine sparks renewed controversy but clinical trials are pushing ahead

A government official’s claim that he was dismissed from his role overseeing the nation’s research into COVID-19 therapies because he refused to more broadly make available hydroxychloroquine highlights the growing tension between the scientific community’s approach to clinical testing and a president in search of a cure.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.